Drug
Raltegravir clinical trials
Also written Isentress and MK-0518.
Keep track of what changes. Save the raltegravir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
174 studies that test it; most in 2008 (35)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 13 |
| 2008 | 35 |
| 2009 | 25 |
| 2010 | 29 |
| 2011 | 14 |
| 2012 | 12 |
| 2013 | 11 |
| 2014 | 13 |
| 2015 | 8 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 147
Merck Sharp & Dohme LLC (14) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · ANRS, Emerging Infectious Diseases (6) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (5) · Radboud University Medical Center (5) · University of California, San Francisco (5) · Kirby Institute (4) · Germans Trias i Pujol Hospital (4)
Often tested with
Tested in the same studies.
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (13) · Lamivudine (11) · Tenofovir (10) · Ritonavir (10) · Emtricitabine (8) · Maraviroc (8) · Atazanavir (7) · Darunavir (6)
Related medicines
As reviewed, each with the page that says it.
- One of Integrase Inhibitors source
Studies
Open first, then newest update. How each study uses raltegravir is read from its arms, and is right about nine times in ten.
Testing it · 174
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02140255Written as Raltegravir (RAL)
- The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.RecruitingPhase 4Ottawa Hospital Research InstituteNCT04258475Written as Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.
- The Effect of Antacids and Multivitamins on RaltegravirCompletedPhase 1Helen ReynoldsNCT01784302Written as Raltegravir 400 mg
- Renal Transplantation and Raltegravir in HIV-Infected PatientsCompletedPhase 3ANRS, Emerging Infectious DiseasesNCT01453192Written as Raltegravir
- Raltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsCompletedPhase 1/2ANRS, Emerging Infectious DiseasesNCT01022476Written as Raltegravir potassium
- Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRALCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02212379Written as raltegravir and etravirine
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line RegimenCompletedPhase 4Kirby InstituteNCT00931463Written as raltegravir
- Safety & Efficacy of Dual Therapy With Raltegravir/LamivudineCompletedPhase 3Juan A. ArnaizNCT02284035Written as Raltegravir/3TC
- Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAMCompletedPhase 3Judit PichNCT03311945Written as Raltegravir
- Bone and Body Comp: A Sub Study of the SECOND-LINE StudyCompletedPhase 4Kirby InstituteNCT01513122Written as raltegravir
- Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDYCompletedPhase 3Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaNCT03029689Written as Raltegravir
- Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current RegimenTerminatedPhase 3Judit PichNCT03333083Written as Raltegravir
- Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV InfectionTerminatedPhase 2/3Fundação Bahiana de InfectologiaNCT01854762Written as Raltegravir
- Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected PatientsCompletedPhase 4Central Institute of Epidemiology, Moscow, RussiaNCT01059422Written as Raltegravir; Abacavir/Lamivudine
- Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease InhibitorsCompletedPhase 3IrsiCaixaNCT01480713Written as Isentress® (Raltegravir, 400 mg every 12 hours)
- Combination Antiretroviral Therapy (cART) for PBCCompletedPhase 2University of AlbertaNCT03954327Written as Raltegravir
- Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected PatientsCompletedPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT02210715Written as Isentress.
- Raltegravir for HAM/TSPCompletedEarly Phase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT01867320Written as Raltegravir
- R5 Integrase Study in HIV-1 Naive PatientsCompletedNot applicableUniversity of Maryland, BaltimoreNCT01204905Written as Raltegravir and Maraviroc in combination
- HIV Non Occupational Post-Exposure Prophylaxis (PEP)CompletedPhase 4Fenway Community HealthNCT00594646Written as TRUVADA + Raltegravir
See all 174 studies that test raltegravir →
Given in every arm · 13 — raltegravir is usual care beside what is tested
- Research In Viral Eradication of HIV ReservoirsCompletedPhase 2Imperial College LondonNCT02336074Written as Raltegravir
- Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor RaltegravirCompletedPhase 1Radboud University Medical CenterNCT01288417Written as raltegravir
- The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)CompletedPhase 1Radboud University Medical CenterNCT01246804Written as raltegravir single dose
- Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/EmtricitabineCompletedPhase 3Germans Trias i Pujol HospitalNCT00808002Written as Raltegravir
- HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsCompletedPhase 2ViiV HealthcareNCT01384734Written as Raltegravir 400 mg
- EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia LymphomaCompletedPhase 1/2Washington University School of MedicineNCT01000285Written as Raltegravir
- A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)CompletedPhase 1Merck Sharp & Dohme LLCNCT01000818Written as MK0518 (Raltegravir)
- Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV MedsCompletedPhase 4Johns Hopkins UniversityNCT01285050Written as raltegravir
- Investigation of Faldaprevir Effect on Pharmacokinetics of RaltegravirCompletedPhase 1Boehringer IngelheimNCT01785160Written as Raltegravir
- Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.CompletedPhase 1/2Gilead SciencesNCT01565889Written as RAL
- Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral ReservoirCompletedPhase 2Robert L. MurphyNCT00976404Written as ART intensification (raltegravir)
- SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoCTerminatedPhase 3Boehringer IngelheimNCT00440271Written as Optimized Background Regimen (OBR)
- Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected SubjectsCompletedPhase 1St Stephens Aids TrustNCT00765271Written as Raltegravir
As the comparator · 6 — what is tested is compared with raltegravir
- A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive AdultsCompletedPhase 3ViiV HealthcareNCT01231516Written as Raltegravir
- Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)CompletedPhase 3Merck Sharp & Dohme LLCNCT02131233Written as Raltegravir
- Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisCompletedPhase 3ANRS, Emerging Infectious DiseasesNCT02273765Written as Tenofovir + lamivudine + raltegravir
- A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyCompletedPhase 3ViiV HealthcareNCT01227824Written as raltegravir
- Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirCompletedPhase 3Gilead SciencesNCT00708162Written as Raltegravir
- Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 InfectionStatus unknownPhase 3Peking Union Medical CollegeNCT02219672Written as Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir
Codes
What other systems call raltegravir · ClinicalTrials.gg INT006558
- MeSH (NLM) D000068898Raltegravir PotassiumConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 22VKV8053URALTEGRAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 719872Confirmed FDA, Wikidata
- Wikidata Q421552raltegravirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72837RaltegravirOne source FDA
- DrugBank DB06817One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068898 | Raltegravir Potassium | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 22VKV8053U | RALTEGRAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 719872 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421552 | raltegravir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72837 | Raltegravir | One source FDA |
| DrugBank | DB06817 | — | One source Wikidata |
Also registered as raltegravir potassium (UNII 43Y000U234 · RxNorm 1235585).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.